Introduction
Salmonella enterica serovar Typhi (S. Typhi) is a humanrestricted pathogen that is the primary cause of typhoid. High incidence of typhoid has been frequently reported in the African regions (Sub-Saharan Africa) [1] , Asian regions (India, Indonesia, China, Pakistan, and Vietnam) [2, 3] , Central and South America, the Middle East and a few Southern and Eastern European countries [4] . The worldwide incidence of typhoid fever is estimated to be around 22 million with at least 200,000 deaths annually [4, 5] . With the emergence of multi drug-resistant strains of Salmonella, its management has further become complicated [6] .
It resides in the lymphatic tissues of bloodstream, liver, small intestine and spleen of infected people [7] . People residing in slump areas and under unhygienic conditions are more prone to infection and thus in more need of vaccination [8] .
S. Typhi biosynthesizes the virulence capsular polysaccharide (Vi; an important virulence factor during infection) thereby making it different from that of other serovars of Salmonella [9] . Three major antigens have been identified in S. Typhi ( Figure 1A (i)): (a) the capsular polysaccharide or Vi antigen; (b) the O or somatic antigen (cell-wall lipopolysaccharide), which corresponds to the endotoxin; and (c) the H or flagellar antigen, which is a protein [10] .
Vi antigen is a linear homopolymer made up of α-1-4-linked N-acetyl galactosaminuronate (GalNAcA); with 60-70% of the monomeric units O-acetylated at the C-3 position [11] [12] [13] and has a molecular mass of >200 kDa ( Figure 1A (ii)). Vi antigen was first discovered by Felix and Pitt [14] . It is present mainly in S. Typhi and Salmonella paratyphi C (S. paratyphi C), as well as Salmonella dublin (S. Dublin) and Citrobacter freundii (C. freundii) [15, 16] . It is an antigen that enhances S. Typhi virulence in mice and has been shown to induce immune response in rabbits [13, 14, 17] . The in vitro studies have shown that Vi is antiopsonic and antiphagocytic [18] , reduces the level of secretion of S. Typhi-induced tumor necrosis factor α (a marker of
Biosynthesis and expression of Vi antigen
The Vi antigen, biosynthesis and expression is controlled by three separated loci, viaA, viaB, and ompB on the S. Typhi chromosome [23] [24] [25] . The via A locus at centisome 43 on the S. Typhi chromosome [26] plays an important role in the regulation of Vi antigen synthesis. The viaB locus is located in Salmonella pathogenicity island 7 (SPI 7) and is important for biosynthesis and expression of Vi polysachharide. The ompB locus consists of the ompR and envZ genes which are present at centisome 92 on the S. Typhi chromosome and at centisome 74 on the S. Typhimurium chromosome [23, 26, 27] ; it plays important role in the expression and regulation of Vi polysachharide [25] . The ompR -mutants of S. Typhi displayed a marked decrease in OmpC and OmpF porin expression, and also showed a loss of Vi antigen synthesis [28] . Functions of all the three loci are discussed here in detail.
The viaB locus, a part of SPI-7
The genes required for Vi biosynthesis and expression (viaB locus) are located in a 133.5 kb chromosomal region called Salmonella pathogenicity island 7 (SPI-7; Figure 2A ). SPI-7 was first discovered as a large The reaction may be initiated by C-6 oxidation of UDP GlcNAc (b), followed by epimerization at C-4 of the resulting UDP GlcNAcA (d) to give (e) (Pathway 1 in red). Alternatively, the reaction may proceed with epimerization at C-4 of (b) to give UDP GalNAc (c), followed by oxidation of (c) at C-6 to give (e) (Pathway 2 in blue). Clearly, the substrate specificity of TviB and TviC will determine whether the biosynthesis of Vi antigen proceeds by Pathway 1 or 2. Panel (B) modified from Zhang et al. [13] .
insertion in the genome of S. Typhi and is the largest genomic island so far identified in Salmonella [29] . SPI-7 is bound by direct repeats, is present between two copies (one partial) of a tRNA gene (pheU) and contains genes encoding known pathogenicity determinants, including SopE, phage encoding the sopE effector protein of SPI-1 [30] and type IV pili [31, 32] and a putative type IV secretion system [29] . SPI-7 is an unstable genetic element that can undergo precise excision, indicating a possible role in the lateral transfer of this region among Gram-negative bacteria [33] . Functional and bioinformatics analyses suggest that SPI-7 has a mosaic structure and may have evolved as a consequence of several independent insertion events. Sequence analysis of the SPI-7 region from S. Typhi revealed significant synteny with clusters of genes from a variety of soil saprophytic bacteria and phytobacteria, raising the possibility that SPI-7 and viaB may have originated from soil sources [34] . Studies have shown that one of the S. Typhi strains was highly invasive, with a deletion in the viaB locus, which can be explained by the production of the Type III secretion systems (T3SS) of SPI-1 [35, 36] .
There are 10 genes on viaB locus, out of which four are tvi genes (tviBCDE), for the biosynthesis of Vi polysaccharide; five are vex genes vexABCDE, for the Vi antigen export (Figure 2A ) [37] [38] [39] ; and the tviA gene, which encodes a regulatory protein, which all play a role in coordinating the expression of Vi antigen, flagella and a number of genes required for host invasion [21, 25, [40] [41] [42] .
Zhang et al. [13] have explained analysis of Vi polysaccharide biosynthesis that it is synthesized from UDP-N-acetyl glucosamine in a series of steps requiring TviB, TviC, and TviE, where tviB encodes a dehydrogenase, tviC encodes an epimerase and tviE [21] . encodes a glycosyl transferase ( Figure 1B ). The role of tviD is not clear, but it appears to encode a cytochrome P-450-like enzyme.
For the export of Vi antigen, VexA, VexB, VexC and VexD polypeptides form the ABC transporter and the VexE polypeptides serves as the anchoring protein [38, 43, 44] (Figure 2A) .
A putative lipoprotein signal sequence is present in VexA. This may therefore be present in the outer membrane and helps in translocating the Vi antigen across the outer membrane of the bacteria [38, 41, 45] . VexB and VexD are highly hydrophobic integral membrane proteins with several membrane-spanning domains [44, 46] , VexC is the ATP-binding protein [44] . The VexA-, VexB-and VexC-defective mutants are not able to translocate Vi polysaccharide across the outer membrane, which gets accumulated in cytoplasm. vexE mutants of S. Typhi Ty2 are capable of synthesizing the Vi polysaccharide and exporting it. However, it is not expressed on surface of the cell [46] . Thus, VexE is necessary for cell surface expression of the Vi capsule [21] .
Regulation of Vi polysaccharide synthesis
The regulation of Vi polysaccharide synthesis is complex. It is tightly controlled what ensures that the required level of Vi polysaccharide is produced all the time, even though the bacteria may encounter different host environments at different stages of infection. The via A locus involved in its regulation is homologous to the rcsB gene, which is associated with a positive regulation of synthesis of Vi polysaccharide in E. coli [40, 47] and the ompR-envZ two-component regulatory system [25] . Functional viaA genes are present not only in Vi-expressing strains of Salmonella and Citrobacter, but also in E. coli and Salmonella enterica serovar Typhimurium (S. Typhimurium) [23, 24] . Cloning, sequencing and complementation studies have shown that the viaA locus of S. Typhi comprises of both rcsB and rcsC genes. High degree of homology is seen when the predicted amino acid sequences of the RcsB protein and that of the C-terminal region of RcsC protein of S. Typhi are compared with the analogous proteins of E. coli (98% and 86%, respectively). Further studies have shown that in the C-terminal domain of RcsB, contains a DNA binding motif of helix turn helix type [43, 45] . Figure 2B outlines the current understanding of this regulation. Two different component systems consisting of rcsB-rcsC (viaA locus) [41] and ompR-envZ (ompB locus) [42] , respond to changes in osmolarity, regulate Vi antigen synthesis. TviA (VipR), which is a positive regulator, initiates its own synthesis by binding to a site upstream of the promoter of its own gene [44] and upon interaction with RcsB it accelerates optimal transcription of genes involved in the synthesis of the Vi antigen [25, 41, 43, 46] . There is a premature termination of transcription initiated at the promoter of tviA gene at the junction of tviA-tviB genes if TviA or RcsB are not present. This is due to the presence of a putative rho independent terminator present in this region that gets activated [46] .
In addition to activating expression of the S. Typhispecific Vi capsular antigen, the TviA protein represses important virulence factors that are highly conserved within the genus Salmonella. These include genes encoding flagella and T3SS-1, whose expression in S. Typhi is reduced by a TviA-mediated repression of the master regulator FlhDC [48] . TviA markedly reduced flagellin repression within 2 hours of bacterial growth at an osmolarity encountered in tissue [42] . TviA-mediated flagellin repression thus occurs within the time frame required for bacterial translocation across an epithelial barrier in vivo. Similarly, TviA activates expression of the Vi capsular antigen when S. Typhi transits from the intestinal lumen into tissue in a ligated ileal loop model [49, 50] .
S. Typhi resides mainly within phagocytic cells and therefore Vi expression is conducively low or absent within phagocytes. In a study, Janis et al. [51] showed that S. Typhimurium carrying the whole SPI-7 regulates in vivo Vi expression within phagocytic cells of mice at different times after systemic infection. It has been shown that replacing the natural tviA promoter with the promoter of the SPI-2 gene ssaG resulted in sustained Vi expression in the liver and spleen and triggered detectable levels of all IgG subclasses specific for Vi; Vi expression was also found to be downregulated in the liver and spleen with the progression of infection.
Vi expression is regulated by environmental stimuli, including osmolarity. Low and medium osmolarity favors its expression. Further, its expression may often suppress the lipopolysaccharide (LPS) O-antigen synthesis [41, 45] . The aqueous environments with osmolarity 60 mM NaCl or less as well as physiological systems such as blood and the cell cytoplasm, with 150 mM of NaCl (310 mosmol) or equivalent salt concentration provide favourable conditions for its synthesis [52] [53] [54] . Studies have shown that high-level production of Vi antigen is achieved by culturing S. Typhi Ty2 strains in 446 mosmol, ~170 mM NaCl [54, 55] . The Vi antigen expression reduces the adherence and invasion of epithelial cells by the bacteria [45] . However, these bacteria develop increased resistance to macrophages killing [19] . This suggests that the Vi antigen expression under these osmolarities provides protection to bacterial cells from the complementmediated actions of antibodies against the O-antigen [20] .
In addition, at low osmolarity, RcsB, acting in association with TviA, negatively controls the transcription of flhDC, which is apparently required for activation of iagA (hilA), invF and sipB (encoding the proteins involved in cell invasion) [41, 42] (Figure 2B ). There is a significant increase in transcription of iagA, invF, and sipB and decrease in the transcription of genes involved in the Vi biosynthesis [41] under high osmolarity environments of intestinal lumen equivalent to 300 mM NaCl or greater [54] . These conditions, however, favor increased invasion of the epithelial cells by S. Typhi as well as make the bacteria less resistant to macrophages killing thus favoring their survival [19] . Studies have shown that at high osmolarity (≥300 mM NaCl), S. Typhi GIFU1007 does not synthesize and express Vi capsule and the bacteria achieve higher invasion index along with the high secretion of SipC protein [56, 57] .
In Salmonella, an alternative sigma factor (σ/RpoS) is encoded by the rpoS gene. This acts as a key regulator and helps the bacteria to survive under stress conditions such as acid shock, transition to stationary phase, osmotic and oxidative stress [58] . It also helps in the expression of genes, spvR, A, B, C and D responsible for the virulence of S. Typhimurium [59, 60] and controls genes involved in the colonization of Peyer's patches and persistence in mice. The rpoS gene is induced under high osmolarity conditions [61, 62] . While the role of rpoS in the S. Typhi virulence has not been explored extensively, studies have shown that rpoS gene might be involved in the S. Typhi virulence as the RpoS -strains of S. Typhi are less cytotoxic and survive better inside the resting THP-1 macrophages without induction of apoptosis than RpoS + strains [63] . A mutation in rpoS renders S. Typhi less cytotoxic to THP-1 macrophages and although the mutants survive similarly as in wild-type strain; the mutants were less invasive to epithelial cells [64] . Recent studies indicated that the allelic state of the rpoS gene and over-expression of Vi antigen are correlated. It was shown that at low and medium osmolarities, RpoS -strains increases synthesis of Vi polysaccharide, whereas RpoS + strains lowers syntheses of Vi polysaccharide and under high osmolarity conditions (≥300 mM NaCl), RpoS -strains showed less or null expression of Vi polysaccharide, RpoS + strains showed overexpression of Vi polysaccharide [65] . It was shown that RpoS is an important factor which can be used in recombinant attenuated Salmonella vaccines development as it regulates Vi antigen synthesis and helps in VW variation in S. Typhi [65, 66] .
Vaccines
Vaccination is one of the most effective methods of controlling infectious diseases including typhoid, especially protecting the population living in endemic zones [67, 68] . Currently two licensed vaccines against Salmonella are in use globally: Vi polysaccharide vaccine and Ty21a live attenuated vaccine [69] . Vivotif Berna ® is an attenuated live Salmonella Typhi Ty21a strain, generated by chemical mutagenesis of parental virulent strain of Salmonella Typhi Ty21 using nitrosoguanidine [70] . Vivotif is highly immunogenic, but an important practical shortcoming is its three to four dosage requirement every alternate day [71] . The other licensed typhoid vaccine is Typhim Vi ® which is the purified Vi antigen from S. Typhi. Vaccination with Typhim Vi provides 55-75% protection with a single dose [6, 72] . The vaccine is given subcutaneously at a single dose of 25 μg to persons over 2 years of age, confers protection within 7-10 days post-inoculation, and requires 3-year boosters [73, 74] . Immunization with this vaccine has been shown to be effective and stimulates protective antibody response [10] .
Typhoid fever vaccines have been evaluated among middle-and low-income populations in endemic countries [2, 75] and also have been used predominantly among travellers from developed countries [76] . However, there is decline in the number of typhoid cases through various typhoid vaccination programs in countries like Thailand, China, Vietnam, India [77] Indonesia and Pakistan [2] . Recommendation have been made to the World Health Organization (WHO) to design more effective programs for controlling outburst of typhoid epidemics with main emphasis on improving water quality and sanitation, and antimicrobial treatment of infected people. Earlier, the vaccines were given in multiple doses which were accompanied by adverse reactions. Now, due to the implementation of proper water and sanitation management, formulation of safe vaccines with simple doses [76] and mass awareness of such vaccinations programs have let to successful control in typhoid endemic countries [3, 78] .
Further, in a report prepared by WHO in 2008 [79] it was suggested to its member states to make proper use of Ty21a and Vi vaccines for combating typhoid in various endemic countries with targeted implementation to high risk groups such as infants and school age children. Such locally produced single dose vaccines would be cost effective and make the mass immunization affordable [80] .
Current prophylaxis and treatment
Though vaccination is the most suitable way for controlling and preventing infectious diseases, it confers varied protection to different individuals by inducing variable degree of immune responses by them. Studies designed to measure the immune response variation among different individuals have shown differences in post-typhoid vaccination antibody levels in 23-40% patients [81, 82] . This variation in immune response is due to differences at the genetic level along with environmental factors. Studies regarding genetic factors responsible for the immunological response to a vaccine may be helpful to develop a vaccine that can overcome immunogenetic restrictions [8] . Studies in endemic areas have reported that around 19-58% of patients are often exposed to S. Typhi and other related infections and therefore develop protective levels of anti-Vi antibodies in the serum prior to vaccination [22, 83, 84] . Such observation suggest that the vaccines can induce a strong post vaccination antibody levels in individuals with/without pre-vaccination antibody levels against S. Typhi [8] .
The Vi antigen is believed to block toll-like receptor (TLR) recognition of pathogen associated molecular patterns and allows S. Typhi to spread systemically by resisting complement-mediated phagocytosis. Reduced TLR-mediated cell signalling provides an important immune evasion mechanism involving down-regulated TLR-mediated immune response [85, 86] . Experimental studies on human colonic tissue explants have revealed that the Vi polysaccharide decreases the TLR-mediated IL-8 signalling that results in evasion of the TLRmediated host response and neutrophiles infiltration in the intestinal mucosa [87] . Toll-interlukin 1 domain which is responsible for signal transduction is present in all toll-like receptors. The IL1RL1 (Interlukin 1 receptor like 1) gene is important for the antibody response elicited by the Vi vaccine and is associated with this signalling pathway [8] .
Vi vaccine acts in T-cell independent manner. It does not need the help of cognate T cells for stimulating the B-cells and non-cognate T-cells [88] [89] [90] . However, such T-cell independent vaccines do not produce antigenspecific CD4+ T cell helper cells and therefore evoke a low immune response in infants (<2 years of age) [91] . In the absence of CD4+ T cell helper cells, the memory B cells cannot be produced for long term, therefore booster doses of Vi PS vaccine is needed after every 2-3 years [76, 92] .
The usefulness of the Vi vaccine, as has been shown for other capsular polysaccharides, is limited by its age-related immunogenicity and its T-cellindependent properties; i.e., it does not elicit protective levels of antibodies in infants and young children, and reinjection at any age does not induce a booster effect [93] . These T-cell-independent antigens induce only IgM antibodies, which are poorly protective in infants (Figure 3 ). These limitations restrict Vi from the routine immunization program for infants and children [94] .
To overcome the limitations of the age-related and T-cell-independent immunogenicity of the vaccine, it is necessary to conjugate the Vi polysaccharide with a protein to get the desired results. Conjugation of capsular polysaccharides to a carrier protein renders them immunogenic in infants and capable of eliciting memory, booster responses and induces IgG antibodies because T cells recognize the complex of a peptide with a major histocompatibility complex (MHC) molecule on the antigen-presenting cell (Figure 3) [94] .
A new such conjugate vaccine, Vi-rEPA is under development, which includes Vi antigen of S. Typhi coupled to recombinant mutant of Pseudomonas aeruginosa exoprotein A (Vi-rEPA) [95] . It has been shown to safe and immunogenic in Vietnamese children aged 2 to 5 years, providing protective efficacy of 91.5% [93, 96] and is undergoing evaluation in younger age groups. The resultant conjugate (Vi-rEPA) enhanced the immunogenicity of Vi and gave it T-cell-dependent properties (Figure 3) . Vi-rEPA elicited a booster response in children 2 to 4 years old, whose levels of IgG Vi antibody were approximately three times higher than those elicited by Vi in children 5 to 14 years old [93, 97] .
In a study, an anti-typhoid fever conjugate vaccine was composed of the C. freundii capsular polysaccharide covalently coupled to the non toxic mutant of diphtheria toxin CRM197 (Figure 3) . C. freundii WR7011 has been chosen as source of Vi instead of S. Typhi (Ty2). Vi-CRM 197 proved immunogenic in animal studies, even without adjuvant [97, 98] . Anti-Vi IgG levels were similarly elicited by Vi-CRM 197 and were also comparable to those elicited by VirEPA at NIH. Unlike rEPA, CRM 197 is licensed for human use in several efficacious conjugate vaccines already used in hundreds of millions of children [99] [100] [101] . Its use as carrier protein should facilitate the development of a commercially viable, effective Vi conjugate vaccine, especially for young children in low income countries; this may also simplify its pathway to licensure [98] .
Many more conjugate vaccines are under use to treat other diseases like Haemophilus influenzae b (Hib) conjugate vaccines (PedvaxHIB, ActHIB, Hiberix) for Hib infection (http://www.cdc.gov/mmwr/ preview/mmwrhtml/00022818.htm, http://www.cdc. gov/ncidod/dbmd/diseaseinfo/haeminfluserob_t.htm) and Pneumococcal conjugate vaccine (PCV) (Prevnar, Synflorix and Prevnar 13) for pneumonia (http://www. cdc.gov/mmwr/preview/mmwrhtml/mm5909a2.htm, http://www.gsk.com/media/pressreleases/2009/2009_ pressrelease_10039.htm), which are highly effective to protect infants and young children and are in routine use in developed countries and recently in developing countries.
Shortfalls in both licensed typhoid vaccines and a greater understanding of the genetics of S. Typhi virulence and recombinant DNA technology promotes the search for a more efficacious and better defined vaccine [6] . In a study, Jansen et al. [103] shown that S. Typhimurium harbouring the entire SPI-7 region which encodes the Vi locus and expresses the Vi polysaccharide capsule modulates the murine immune response resulting in significant reduction in cellular trafficking of PMN and NK cells and a striking increase in the anti-inflammatory cytokine IL-10 expressed in macrophages, dendritic cells and NK cells in the mouse spleen. This S. Typhimurium/S. Typhi genomic chimera in vitro, has characterized the expression of the Vi polysaccharide capsule and the early innate immune response to infection in the murine model, thereby proposing an improved chimeric typhoid model for developing Vi polysaccharide based vaccines.
It is difficult to develop vaccines against different typhoidal and non-typhoidal salmonellosis caused by large number of serovars and strains of Salmonella. Efficient and safe live attenuated oral vaccines with lesser number of doses are under development [104, 105] . Among these, the upcoming strains are CVD 906, CVD 908-htrA, CVD 909, Ty800 M01ZH09 [106] [107] [108] [109] [110] , (∆cya ∆crp-cdt) [111, 112] [94] .
atpA mutants of S. Typhimurium are strongly attenuated and confer protection against subsequent infections [4, [114] [115] [116] . The development of regulated, delayed attenuated mutants has further helped in combating this problem. In S. Typhimurium it has been shown that by placing the fur, crp, phoPQ and rpoS promoters under control of an arabinose inducible promoter, attenuation in these genes is observed that provides protection in mice [117] . Also, the Salmonella pmi mutants were shown to be both attenuated and protective in mice [4, 118] .
A new recombinant attenuated Salmonella Typhi vaccine (RASTyV) is under clinical trials, expressing a heterologous antigen-Streptococcus pneumoniae surface protein PspA and rpoS, to prevent pneumococcal diseases in infants and children. In this study, three new RASTyV strains were designed and evaluated, with new features including regulated delayed in vivo synthesis of the pneumococcal antigen PspA and regulated delayed in vivo attenuation. It has been shown that all three RASTyV strains are similar to the live attenuated typhoid vaccine Ty21a in their ability to survive in human monocytes and human blood. Immunization with any of the RASTyV strains develops immune responses against PspA and Salmonella antigens and provides protection against S. pneumonia challenge. These strains exhibit a desirable balance between safety and immunogenicity and are currently being evaluated in a Phase 1 clinical trial to determine which of the three RASTyV strains have the optimal safety and immunogenicity profile in human hosts and to enable construction of an antipneumococcal vaccine [66] . These S. Typhi attenuated strains can also be used as potential carriers of antigens from other pathogens.
Various studies on outer membrane proteins (OMPs) of Salmonella have shown to confer protection against typhoid. In our laboratory a novel non-poring 49 kDa OMP of S. Typhi has been purified and characterized, which has been shown to provoke both humoral and cell-mediated immune response, providing 100% protection against high doses of S. Typhimurium challenge in immunized mice. This OMP holds great promise for formulation of a future candidate vaccine against typhoid [105, 119, 120] . Identifying immunogenic S. Typhi antigens expressed during human infection could lead to improved diagnostic assays and vaccines [7, 121] .
Conclusions
S. Typhi causes typhoid fever in humans. The synthesis and expression of the Vi capsular antigen in S. Typhi infection presents a possible explanation for the different clinical manifestation of typhoid fever compared to that of patients infected with non typhoidal Salmonella serovars. The biosynthesis of Vi antigen is a complex process involving number of genes. The regulation of this process involves a number of genes and gene products. These regulatory mechanisms also play key role in pathogenesis of S. Typhi. Capsular polysaccharides are immunogenic in mammals, nontoxic and free of the deleterious effects associated with the whole organism. Immunization with them has been shown to confer protective antibody responses against typhoid fever and is generally considered efficacious. Thus, the Vi capsule is and continues to be a significant focus for the development of a consistent and affordable conjugate typhoid fever vaccine for use in all ages in developing countries.
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